scholarly journals Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

2021 ◽  
Author(s):  
Muzi Li ◽  
Lihong Xu ◽  
Heng Zhao ◽  
Lei Yan ◽  
Yanbo Du
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Hormone Replacement ◽  
Pregnancy Rates ◽  
Clinical Pregnancy ◽  
Control Group ◽  
Live Birth Rates ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Ivf Et

Abstract Gonadotropin-releasing hormone agonist(GnRH-a) is generally added to improve pregnancy outcomes of adenomyosis based hormone replacement therapy cycle. Our objective in this study is to investigate whether adding GnRH-a can obtain better pregnancy outcomes. In this retrospective analysis, a total of 341 patients with adenomyosis complicated in vitro fertilization-embryo transfer(IVF-ET) of the frozen embryo transfer (FET). The control group was only treated by hormone replacement therapy cycles to prepare emdometrium, and the study group was added GnRH-a before using hormone to adjust menstruation period. Based on the similar baseline values and embryological data, there was no significantly difference about their clinical pregnancy rates (40.63% vs 42.54%, P=0.72) and live birth rates (23.75% vs 23.75%, P=0.74) between the control group and the study group. Other secondary outcomes including clinical miscarriage rates, ectopic pregnancy rates, preterm pregnancy rates and term pregnancy rates did not show significant difference between the two groups. Compared with using hormone replacement therapy cycle alone, GnRH-a down-regulation based on hormone replacement therapy cycle may not increase the rates of clinical pregnancy and live birth rates in IVF-ET of FET for infertile patients with adenomyosis.

scholarly journals Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Muzi Li ◽  
Lihong Xu ◽  
Heng Zhao ◽  
Yanbo Du ◽  
Lei Yan
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Live Birth ◽  
Pregnancy Outcomes ◽  
Hormone Replacement ◽  
Gonadotropin Releasing Hormone ◽  
Clinical Pregnancy ◽  
Frozen Embryo Transfer ◽  
Gonadotropin Releasing Hormone Agonist

AbstractGonadotropin-releasing hormone agonist (GnRH-a) is generally added to the improve pregnancy outcomes of hormone replacement therapy cycles among patients with adenomyosis. We aimed to investigate whether adding GnRH-a can result in better pregnancy outcomes. This retrospective analysis included 341 patients with adenomyosis who underwent frozen embryo transfer (FET) after in vitro fertilization (IVF). The control group was treated only with hormone replacement therapy cycles to prepare the endometrium, and GnRH-a was added to the study group before hormone administration to adjust the menstruation cycle. Based on the similar baseline values and embryological data, there was no significant difference in the clinical pregnancy rates (40.63% vs. 42.54%, P = 0.72) and live birth rates (23.75% vs. 23.75%, P = 0.74) of the control and study groups. Other secondary outcomes, including the rates of clinical miscarriage, ectopic pregnancy, preterm birth and term birth, were not significantly different between the two groups. Compared with the hormone replacement therapy cycle alone, GnRH-a downregulation based on a hormone replacement therapy cycle may not increase the rate of clinical pregnancy or live birth of IVF-ET with FET among infertile patients with adenomyosis.

Maintenance of Pregnancy and Obstetric Outcome in Donor Egg Pregnancies

1992 ◽  
Vol 4 (6) ◽  
pp. 712
Author(s):  
J Leeton ◽  
I Calderon ◽  
J Burden ◽  
K Azuma ◽  
P Renou
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Vaginal Delivery ◽  
Hormone Replacement ◽  
Embryo Implantation ◽  
Ovarian Failure ◽  
Obstetric Outcome ◽  
Donor Egg ◽  
Monozygous Twins

Data are presented on the outcome of 43 pregnancies between 1983 and 1991. Maintenance of pregnancy in agonadal women begins at the time of embryo implantation, and initial hormone replacement therapy to prime the endometrium before embryo transfer is an important factor. Synchronization in agonadal women is successful with the variable-length oestrogen replacement regime but can be difficult in ovulating recipients. The outcome of donor egg (DE) pregnancies in this study is comparable to that of IVF pregnancies, with the possible exception of an increased rate of monozygous twins. Pre-eclampsia does not appear to increase significantly in DE pregnancies. Vaginal delivery is possible for DE pregnancies in women with ovarian failure.

Effect of Hormone Replacement Therapy on Ocular Hemodynamics in Postmenopausal Women

2001 ◽  
Vol 11 (3) ◽  
pp. 277-280 ◽  
Author(s):  
H. Atílla ◽  
A. Arslanpençe ◽  
F. Batioğlu ◽  
T. Eryilmaz ◽  
S. Aytaç ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Doppler Ultrasonography ◽  
Hormone Replacement ◽  
Control Group ◽  
Medication History ◽  
The Mean ◽  
Ocular Hemodynamics ◽  
Flow Velocities

Purpose To evaluate the effect of hormone replacement therapy on ocular hemodynamics in postmenopausal women. Methods Ocular Doppler ultrasonography was performed in 20 postmenopausal women on hormone replacement therapy (HRT) and in 20 women without treatment, as the control group. Central retinal artery (CRA), posterior ciliary artery (PCA) and ophthalmic artery (OA) flow velocities and vascular resistances were measured prospectively by a radiologist blinded to the therapy. There were no associated systemic or ocular diseases or any medication history. Results The mean age of the patients on HRT was 50.05 ± 4.5 yrs (range 44 - 62). The mean age of the control group was 52.8 ± 4.09 yrs (range 46 - 65). The mean duration of HRT was 1.6 ± 1.4 yrs (range 3 months - 5 years). There were no differences between the groups in terms of flow velocities, vascular resistivities or pulsatility indices of OA, CRA and PCA (p>0.05). Conclusions HRT is essential in postmenopausal women for relief of vasomotor symptoms, cardioprotection and prevention of osteoporosis. Even though vaso-occlusive complications of hormone preparations have been reported, we did not observe any changes in ocular hemodynamics detectable with Doppler ultrasonography.

Effects of Hormone Replacement Therapy on Muscle Performance and Balance in Post-Menopausal Women

1996 ◽  
Vol 91 (6) ◽  
pp. 685-690 ◽  
Author(s):  
Alison L. Armstrong ◽  
Janet Oborne ◽  
Carol A. C. Coupland ◽  
Marion B. MacPherson ◽  
E. Joan Bassey ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Test Group ◽  
Muscle Performance ◽  
Control Group ◽  
Menopausal Women ◽  
Significant Difference ◽  
Post Menopausal ◽  
Leg Extensor Power

1. A randomized controlled trial of the effect of oral hormone replacement therapy plus calcium compared with calcium alone on balance, muscle performance and falls was conducted over 48 weeks in 116 post-menopausal women (aged 45–70 years), all of whom had suffered a distal radial fracture during the previous 3 months. Treatment was with Prempak C or Premarin 0.625 mg in the test group with 1 g calcium daily (Sandocal) in both groups. Measurements were made of balance, assessed as sway, leg extensor power and self-paced walking speed, at 12-week intervals over 24 weeks. Hand grip strength was measured every 12 weeks for 48 weeks, and falls in the preceding 12 weeks were recorded at each visit. 2. There was no relation between initial levels of oestradiol and any other variable assessed, except body mass. Levels of follicle-stimulating hormone in the test group were in the premenopausal range. There was no significant change attributable to hormone replacement therapy at any time point in any of the outcome variables. The only significant difference was an increase of 4.2% (95% confidence interval 0.7–7.6%) in leg extensor power in the control group (calcium alone) compared with the group treated with hormone replacement therapy. 3. Of the total group, 37% fell again during the year, with three patients suffering a further fracture. Frequent fallers swayed significantly more often than the others, but there was no evidence that their muscle strength was poorer or that the group treated with hormone replacement therapy fell less frequently. 4. Hormone replacement therapy did not increase muscle performance, improve balance or reduce falls over a year in middle-aged women.

scholarly journals Development and Evaluation of Three Immunofluorometric Assays That Measure Different Forms of Osteocalcin in Serum

2000 ◽  
Vol 46 (3) ◽  
pp. 332-337 ◽  
Author(s):  
Sanna-Maria Käkönen ◽  
Jukka Hellman ◽  
Matti Karp ◽  
Pirjo Laaksonen ◽  
Karl J Obrant ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Hormone Replacement Therapy ◽  
Bone Formation ◽  
Diurnal Variation ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Control Group ◽  
Plasma Samples ◽  
Edta Plasma ◽  
Human Osteocalcin

Abstract Background: Circulating human osteocalcin (hOC) has been used as a marker of bone formation. Our aim was to validate three immunofluorometric assays (IFMAs), measuring different forms of hOC. Methods: The two-site IFMAs were based on previously characterized monoclonal antibodies. Assay 2 recognized intact hOC, assays 4 and 9 measured the NH2-terminal mid-fragment and the intact hOC. In addition, assay 9 required hOC to be γ-carboxylated. Results: A 76–79% increase of serum immunoreactive hOC was found in the postmenopausal group compared with the premenopausal group with all IFMAs. With EDTA-plasma samples, the observed increases were lower (49–65%). The hOC concentration in the postmenopausal group receiving hormone replacement therapy was 42–44% lower than that in the postmenopausal control group in both serum and EDTA-plasma samples. The depressed carboxylation in warfarin-treated patients was accompanied by lower results in assay 9. The ratio of assay 9 to assay 4 totally discriminated the warfarin-treated patients from the controls. Assay 9 showed the smallest decreases in measured hOC after storage of serum or plasma for 4 weeks at 4 °C, followed by assay 4 and assay 2. Results from the last assay were <17% of their initial values after 4 weeks of storage. No diurnal variation was observed with assay 9 as opposed to the two other IFMAs. Conclusion: The three assays with their distinct specificity profiles (intact vs fragmented and carboxylated vs decarboxylated hOC) may provide valuable tools for investigating the significance of different hOC forms in various bone-related diseases.

Sign in / Sign up

Export Citation Format

Share Document